| Mrs Caroline Pappas, APRN | |
|
2707 Celanese Rd, Rock Hill, SC 29732-9406 | |
| (803) 366-4157 | |
| Not Available |
| Full Name | Mrs Caroline Pappas |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 2707 Celanese Rd, Rock Hill, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114561685 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 23384 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Medical Center | Rock hill, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Radiology Associates Pllc | 8224002696 | 88 |
News Archive
Policies that helped financially struggling Americans stay in their homes and keep access to water and electricity during the COVID-19 pandemic also helped reduce the spread of the virus, according to a new analysis by Duke University researchers.
Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.
AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Despite abortion being severely legally restricted - and potentially unsafe - in Peru, the incidence of abortion is as high as or higher than the incidence in many countries where it is legal and safe, found researchers from Peru, the United Kingdom and the United States in an article published in CMAJ.
› Verified 8 days ago
| Entity Name | Rock Hill Radiology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972546133 PECOS PAC ID: 8527026517 Enrollment ID: O20041222000087 |
News Archive
Policies that helped financially struggling Americans stay in their homes and keep access to water and electricity during the COVID-19 pandemic also helped reduce the spread of the virus, according to a new analysis by Duke University researchers.
Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.
AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Despite abortion being severely legally restricted - and potentially unsafe - in Peru, the incidence of abortion is as high as or higher than the incidence in many countries where it is legal and safe, found researchers from Peru, the United Kingdom and the United States in an article published in CMAJ.
› Verified 8 days ago
| Entity Name | Sc House Calls Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518048859 PECOS PAC ID: 6800994807 Enrollment ID: O20070613000821 |
News Archive
Policies that helped financially struggling Americans stay in their homes and keep access to water and electricity during the COVID-19 pandemic also helped reduce the spread of the virus, according to a new analysis by Duke University researchers.
Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.
AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Despite abortion being severely legally restricted - and potentially unsafe - in Peru, the incidence of abortion is as high as or higher than the incidence in many countries where it is legal and safe, found researchers from Peru, the United Kingdom and the United States in an article published in CMAJ.
› Verified 8 days ago
| Entity Name | Coastal Radiology Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144270307 PECOS PAC ID: 8224002696 Enrollment ID: O20150513001736 |
News Archive
Policies that helped financially struggling Americans stay in their homes and keep access to water and electricity during the COVID-19 pandemic also helped reduce the spread of the virus, according to a new analysis by Duke University researchers.
Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.
AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Despite abortion being severely legally restricted - and potentially unsafe - in Peru, the incidence of abortion is as high as or higher than the incidence in many countries where it is legal and safe, found researchers from Peru, the United Kingdom and the United States in an article published in CMAJ.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Caroline Pappas, APRN 2707 Celanese Rd, Rock Hill, SC 29732-9406 Ph: (803) 366-4157 | Mrs Caroline Pappas, APRN 2707 Celanese Rd, Rock Hill, SC 29732-9406 Ph: (803) 366-4157 |
News Archive
Policies that helped financially struggling Americans stay in their homes and keep access to water and electricity during the COVID-19 pandemic also helped reduce the spread of the virus, according to a new analysis by Duke University researchers.
Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.
AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Despite abortion being severely legally restricted - and potentially unsafe - in Peru, the incidence of abortion is as high as or higher than the incidence in many countries where it is legal and safe, found researchers from Peru, the United Kingdom and the United States in an article published in CMAJ.
› Verified 8 days ago
Mrs. Mary Jo Barreto, APRN-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: Winthrop University Health Services, Rock Hill, SC 29733 Phone: 803-323-2206 Fax: 803-323-3332 | |
Ms. Wanda Kaye Clark, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1151 Camden Ave, Rock Hill, SC 29732 Phone: 803-909-6363 Fax: 803-909-6364 | |
Marta Pacheco, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1617 Shetland Ln, Rock Hill, SC 29730 Phone: 540-797-4361 | |
Andrea Blakeman, APRN Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1131 Saluda St, Rock Hill, SC 29730 Phone: 803-325-7744 Fax: 803-325-1117 | |
Sarah Elizabeth Christ, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 170 Amendment Ave, Rock Hill, SC 29732 Phone: 803-324-7607 Fax: 800-332-4409 | |
Mr. Gerald Alfred Bracete, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 500 Lakeshore Pkwy, Rock Hill, SC 29730 Phone: 803-909-6363 | |
Sarah Lyn Ruhland, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 197 Piedmont Blvd Ste 100, Rock Hill, SC 29732 Phone: 803-324-1950 Fax: 803-324-1933 |